regardless of encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from PBMs. Such companies are often building limitations to access, like steep expense requirements and PA that hinder user a